Market Access News | pharmaphorum

News

US vulnerable to China's API dominance, says report

China has such a dominant position in pharmaceutical ingredient production that there is a risk it will weaponise access, says a Congressional report.

News

Sarepta rises after FDA adds warning label to Elevidys

Uncertainty ends Sarepta's Duchenne gene therapy Elevidys ends after an FDA label update, with the company's shares on the up despite restrictions.

News

Sanofi's type 1 diabetes drug poised for EU rollout

Sanofi is celebrating an approval recommendation in the EU for Teizeild, a first-in-class drug designed to delay the progression of type 1 diabetes.

News

Kura Oncology and Kyowa Kirin logos with Komzifti pill bottle

Kura scores FDA okay for rival to Syndax's leukaemia drug

Kura has claimed FDA approval for oral menin inhibitor Komzifti for acute myeloid leukaemia, setting up a battle with Syndax's rival Revuforj.

News

NICE backs Roche's non-Hodgkin lymphoma drug Columvi

NICE backs NHS use of Roche's Columvi as a second-line therapy for a form of non-Hodgkin lymphoma affecting thousands of people in the UK each year.

News

FDA unveils swift route to market for personalised drugs

FDA reveals a regulatory pathway for personalised therapies based on 'plausible mechanism', drawing on the bespoke gene-editing treatment of Baby KJ.

US vulnerable to China's API dominance, says report

Sarepta rises after FDA adds warning label to Elevidys

Sanofi's type 1 diabetes drug poised for EU rollout

Kura scores FDA okay for rival to Syndax's leukaemia drug

NICE backs Roche's non-Hodgkin lymphoma drug Columvi

FDA unveils swift route to market for personalised drugs

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

News

Editor's Picks